ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2111

Anti-N-Methyl-D-Aspartate Receptor Encephalitis – Expanding Our Understanding of the Clinical Needs of Pediatric Patients with This Complex Disorder

Katherine A. Battisti1, Tobias J. Tsai2, Angela Pickersgill3 and Sheetal S. Vora4, 1Emergency Medicine, Nationwide Children's Hospital, Columbus, OH, 2Physical Medicine and Rehabilitation, Levine Children's Hospital/Carolinas Medical Center, Charlotte, NC, 3Pediatrics, Levine Children's Hospital, Charlotte, NC, 4Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoimmune diseases, pediatrics and rehabilitation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Although recognized only 10 years ago, anti-N-Methyl-D-Aspartate receptor encephalitis (anti-NMDAR encephalitis) has become a leading cause of encephalitis with an identifiable etiology in pediatric patients1. The clinical presentation of patients with this disorder is quite variable but typically involves acute onset of symptoms with a characteristic progression including movement disorders, psychiatric symptoms, autonomic instability and seizures2. Despite efforts to fully understand this disorder, there continue to be gaps in our knowledge.

Methods: This was a retrospective chart review of patients admitted to a mid-sized tertiary pediatric hospital for medical or rehabilitative services with a diagnosis of anti-NMDAR encephalitis over a 41 month period. Only patients with laboratory evidence of anti-NMDAR encephalitis between the ages of 24 months and 18 years were included in this study.

Results: 12 patients met our inclusion criteria ranging in age from 2 years to 17 years of age with a median age of 9. These patients represent 12.5% of the patients with a diagnosis of encephalitis at our hospital during this time frame. 58% were female. Multiple ethnicities and socioeconomic backgrounds were represented. All but one patient presented with sudden onset of unexplained behavioral change from baseline. Mean time to diagnosis was 17 days. Eleven out of twelve patients had a minimum of 3 of the 8 characteristic symptoms noted in 90% of patients3. One patient died of overwhelming sepsis while immunosuppressed. Only one patient was found to have an associated tumor. 41% of patients required a PICU admission. All of the patients required inpatient rehabilitation. 75% of patients required gastrostomy tube placement. 25% of patients have returned to baseline and another 16% demonstrated functional gains by the most recent follow up. Many are still in the initial 12-24 months of recovery so their outcomes are still undetermined. 3 of the 12 patients in our study had pre-existing cognitive deficits or propensity for them; these patients were noted to all have incomplete recovery.

Conclusion: Though previously described, anti-NMDAR encephalitis may be more common than we recognize. In this study we present 12 cases of anti-NMDAR encephalitis treated at a single center pediatric tertiary care institution. We found no correlation of time to diagnosis with ethnicity or socioeconomic status. Our series corroborates the current literature with most patients presenting with acute unexplained behavioral change. Many patients required intensive care management. Their recovery is prolonged and almost invariably requires inpatient rehabilitation and often gastrostomy tubes. This suggests that management at a tertiary care center and early physical medicine and rehabilitation consultation is recommended. Recovery for these patients is mixed, and though our study is too small to reach statistical significance, we did note a trend in patients with pre-existing cognitive deficits or propensity for them who seem to have diminished recovery compared to patients with no prior history suggesting the need for further research in this area.


Disclosure: K. A. Battisti, None; T. J. Tsai, None; A. Pickersgill, None; S. S. Vora, None.

To cite this abstract in AMA style:

Battisti KA, Tsai TJ, Pickersgill A, Vora SS. Anti-N-Methyl-D-Aspartate Receptor Encephalitis – Expanding Our Understanding of the Clinical Needs of Pediatric Patients with This Complex Disorder [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/anti-n-methyl-d-aspartate-receptor-encephalitis-expanding-our-understanding-of-the-clinical-needs-of-pediatric-patients-with-this-complex-disorder/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-n-methyl-d-aspartate-receptor-encephalitis-expanding-our-understanding-of-the-clinical-needs-of-pediatric-patients-with-this-complex-disorder/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology